ETFs Joinn Laboratories(China)Co.,Ltd. Hong Kong S.E.

6127

CNE100004BP3

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:21 2026-10-29 EDT			5-day change	1st Jan Change
23.24 ^HKD	-5.14%		-12.83%	+12.82%

10-29	Joinn Laboratories (China) Posts Higher Attributable Profit in Q3; Revenue Up	MT
10-28	Joinn Laboratories(China)Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026	CI

ETFs positioned on Joinn Laboratories(China)Co.,Ltd.

Name	YTD change	Weight	AuM
VANGUARD FTSE ALL-WORLD UCITS ETF - USD	+11.03%	-	27,154 M€
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	+5.29%	-	37 M€
ISHARES MSCI CHINA SMALL-CAP ETF - USD	-20.98%	0.14%	67 M€
ISHARES MSCI AC FAREAST EXJPN SC ETF$DIS	-.--%	0.03%	74 M€
ISHARES MSCI AC FAR EAST EX-JAPAN SMALL CAP UCITS ETF - USD	+10.45%	0.03%	74 M€
STATE STREET SPDR S&P EMERGING MARKETS SMALL CAP ETF - USD	+2.09%	0.03%	701 M€
ISHARES MSCI EM SMALL CAP UCITS ETF - USD	+3.55%	0.02%	337 M€
STATE STREET SPDR MSCI EMERGING MARKETS SMALL CAP UCITS ETF - USD	+9.77%	0.02%	611 M€
FRANKLIN FTSE CHINA ETF - USD	-18.70%	0.01%	338 M€
FRANKLIN FTSE CHINA UCITS ETF - ACC - USD	-14.30%	0.01%	1,754 M€
SCHWAB EMERGING MARKETS EQUITY ETF - USD	+6.29%	0%	12,827 M€
VANGUARD FTSE EMERGING MARKETS ALL CAP INDEX ETF - CAD	+7.09%	0%	3,276 M€
VANGUARD ESG EMERGING MARKETS ALL CAP UCITS ETF ACC - USD	+14.40%	0%	117 M€
ISHARES CORE MSCI EMERGING MARKETS IMI INDEX ETF - CAD	+15.80%	0%	3,282 M€
VANGUARD FTSE EMERGING MARKETS SHARES ETF - AUD	-2.08%	0%	1,449 M€
VANGUARD FTSE EMERGING MARKETS ETF - USD	+5.28%	0%	126,032 M€
VANGUARD FTSE EMERGING MARKETS UCITS ETF - USD	+4.26%	0%	3,667 M€
ISHARES MSCI EM IMI SCREENED UCITS ETF - ACCUMULATING - USD	+20.14%	0%	6,575 M€
VANGUARD ESG EMERGING MARKETS ALL CAP UCITS ETF DIST - USD	+12.48%	0%	24 M€
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	+4.70%	0%	33,076 M€
VANGUARD FTSE EMERGING MARKETS UCITS ETF ACCUMULATING - USD	+10.45%	0%	2,339 M€
ISHARES MSCI EM IMI SCREENED UCITS ETF - DISTRIBUTING - USD	+13.87%	0%	1,403 M€
ISHARES CORE MSCI EMERGING MARKETS IMI INDEX ETF - USD	+13.67%	0%	14 M€
VANGUARD FTSE ALL-WORLD EX-US ETF - USD	+11.34%	0%	70,454 M€
VANGUARD TOTAL INTERNATIONAL STOCK ETF - USD	+10.88%	0%	163,510 M€
ELM MARKET NAVIGATOR ETF - USD	+7.43%	0%	594 M€
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	+4.06%	0%	52 M€
ISHARES CORE MSCI ALL COUNTRY WORLD EX CANADA INDEX ETF - USD	0.00%	0%	25 M€
ISHARES CORE MSCI ALL COUNTRY WORLD EX CANADA INDEX ETF - CAD	+14.13%	0%	3,286 M€
VANGUARD FTSE GLOBAL ALL CAP EX CANADA INDEX ETF - CAD	+13.81%	0%	2,612 M€
RETURN STACKED GLOBAL STOCKS & BONDS ETF - USD	+7.68%	0%	526 M€
VANGUARD TOTAL WORLD STOCK ETF - USD	+11.99%	0%	81,610 M€
DEFINED DURATION 20 ETF - USD	+11.61%	0%	19 M€
RPAR RISK PARITY ETF - USD	+1.26%	0%	580 M€
THE BRINSMERE FUND GROWTH ETF - USD	+8.53%	0%	391 M€
VANGUARD ESG GLOBAL ALL CAP UCITS ETF - ACCUMULATING - USD	+18.00%	0%	1,190 M€
VANGUARD ESG GLOBAL ALL CAP UCITS ETF - DISTRIBUTING - USD	+16.81%	0%	699 M€
VANGUARD FTSE ALL-WORLD UCITS ETF ACCUMULATING - USD	+17.90%	0%	56,205 M€
VANGUARD ALL-EQUITY ETF PORTFOLIO - CAD	+15.25%	0%	12,086 M€
VANGUARD GROWTH ETF PORTFOLIO - CAD	+10.69%	0%	7,793 M€
UPAR ULTRA RISK PARITY ETF - USD	-0.53%	0%	59 M€
DISCIPLINE FUND ETF - USD	-.--%	0%	73 M€

1 2

Joinn Laboratories China Co Ltd is a China-based company primarily engaged in the pharmacology and toxicology research of new drugs. The Company operates its businesses through three segments. The Non-clinical Drug Research Service segment mainly provides non-clinical drug safety evaluation services, pharmacodynamic research services, and pharmacokinetic research services. The Clinical Services and Others segment mainly provides pre-market clinical services and pharmacovigilance services for drugs. The Experimental Model Supply segment is responsible for the production and sales of experimental models and their ancillary products. The Company conducts its businesses both in the domestic market and overseas markets.

Employees

2,500

Sector

Biotechnology & Medical Research

Calendar

10-29 Earnings release - Q3 2026

More about the company